A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, C. | - |
dc.contributor.author | Ryu, D.-K. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Kim, Y.-I. | - |
dc.contributor.author | Seo, J.-M. | - |
dc.contributor.author | Kim, Y.-G. | - |
dc.contributor.author | Jeong, J.-H. | - |
dc.contributor.author | Kim, M. | - |
dc.contributor.author | Kim, J.-I. | - |
dc.contributor.author | Kim, P. | - |
dc.contributor.author | Bae, J.S. | - |
dc.contributor.author | Shim, E.Y. | - |
dc.contributor.author | Lee, M.S. | - |
dc.contributor.author | Kim, M.S. | - |
dc.contributor.author | Noh, H. | - |
dc.contributor.author | Park, G.-S. | - |
dc.contributor.author | Park, J.S. | - |
dc.contributor.author | Son, D. | - |
dc.contributor.author | An, Y. | - |
dc.contributor.author | Lee, J.N. | - |
dc.contributor.author | Kwon, K.-S. | - |
dc.contributor.author | Lee, J.-Y. | - |
dc.contributor.author | Lee, H. | - |
dc.contributor.author | Yang, J.-S. | - |
dc.contributor.author | Kim, K.-C. | - |
dc.contributor.author | Kim, S.S. | - |
dc.contributor.author | Woo, H.-M. | - |
dc.contributor.author | Kim, J.-W. | - |
dc.contributor.author | Park, M.-S. | - |
dc.contributor.author | Yu, K.-M. | - |
dc.contributor.author | Kim, S.-M. | - |
dc.contributor.author | Kim, E.-H. | - |
dc.contributor.author | Park, S.-J. | - |
dc.contributor.author | Jeong, S.T. | - |
dc.contributor.author | Yu, C.H. | - |
dc.contributor.author | Song, Y. | - |
dc.contributor.author | Gu, S.H. | - |
dc.contributor.author | Oh, H. | - |
dc.contributor.author | Koo, B.-S. | - |
dc.contributor.author | Hong, J.J. | - |
dc.contributor.author | Ryu, C.-M. | - |
dc.contributor.author | Park, W.B. | - |
dc.contributor.author | Oh, M.-D. | - |
dc.contributor.author | Choi, Y.K. | - |
dc.contributor.author | Lee, S.-Y. | - |
dc.date.accessioned | 2021-12-04T14:41:31Z | - |
dc.date.available | 2021-12-04T14:41:31Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2021-01-12 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129386 | - |
dc.description.abstract | Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19. © 2021, The Author(s). | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Nature Research | - |
dc.subject | angiotensin converting enzyme 2 | - |
dc.subject | ct p 59 | - |
dc.subject | d614g protein | - |
dc.subject | fab protein | - |
dc.subject | Fc receptor | - |
dc.subject | human monoclonal antibody | - |
dc.subject | immunoglobulin G | - |
dc.subject | rbd protein | - |
dc.subject | regdanvimab | - |
dc.subject | remdesivir | - |
dc.subject | unclassified drug | - |
dc.subject | virus RNA | - |
dc.subject | virus spike protein | - |
dc.subject | vitronectin | - |
dc.subject | ACE2 protein, human | - |
dc.subject | coronavirus spike glycoprotein | - |
dc.subject | monoclonal antibody | - |
dc.subject | neutralizing antibody | - |
dc.subject | protein binding | - |
dc.subject | spike protein, SARS-CoV-2 | - |
dc.subject | virus antibody | - |
dc.subject | adult | - |
dc.subject | animal experiment | - |
dc.subject | animal model | - |
dc.subject | animal tissue | - |
dc.subject | antibody library | - |
dc.subject | Article | - |
dc.subject | bacterium isolation | - |
dc.subject | clinical assessment | - |
dc.subject | clinical evaluation | - |
dc.subject | controlled study | - |
dc.subject | convalescence | - |
dc.subject | coronavirus disease 2019 | - |
dc.subject | crystal structure | - |
dc.subject | female | - |
dc.subject | hamster | - |
dc.subject | human | - |
dc.subject | human cell | - |
dc.subject | in vitro study | - |
dc.subject | in vivo study | - |
dc.subject | male | - |
dc.subject | Mustela putorius furo | - |
dc.subject | nonhuman | - |
dc.subject | pandemic | - |
dc.subject | peripheral blood mononuclear cell | - |
dc.subject | protein domain | - |
dc.subject | protein interaction | - |
dc.subject | receptor binding | - |
dc.subject | rhesus monkey | - |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | - |
dc.subject | stereospecificity | - |
dc.subject | symptom | - |
dc.subject | therapy effect | - |
dc.subject | virus load | - |
dc.subject | virus replication | - |
dc.subject | animal | - |
dc.subject | chemistry | - |
dc.subject | Chlorocebus aethiops | - |
dc.subject | disease model | - |
dc.subject | drug effect | - |
dc.subject | drug therapy | - |
dc.subject | immunology | - |
dc.subject | Mesocricetus | - |
dc.subject | molecular model | - |
dc.subject | mononuclear cell | - |
dc.subject | protein conformation | - |
dc.subject | Vero cell line | - |
dc.subject | Cricetinae | - |
dc.subject | Macaca mulatta | - |
dc.subject | Mustela | - |
dc.subject | SARS coronavirus | - |
dc.subject | Angiotensin-Converting Enzyme 2 | - |
dc.subject | Animals | - |
dc.subject | Antibodies, Monoclonal | - |
dc.subject | Antibodies, Neutralizing | - |
dc.subject | Antibodies, Viral | - |
dc.subject | Chlorocebus aethiops | - |
dc.subject | COVID-19 | - |
dc.subject | Disease Models, Animal | - |
dc.subject | Female | - |
dc.subject | Ferrets | - |
dc.subject | Humans | - |
dc.subject | Leukocytes, Mononuclear | - |
dc.subject | Macaca mulatta | - |
dc.subject | Male | - |
dc.subject | Mesocricetus | - |
dc.subject | Models, Molecular | - |
dc.subject | Protein Binding | - |
dc.subject | Protein Conformation | - |
dc.subject | SARS-CoV-2 | - |
dc.subject | Spike Glycoprotein, Coronavirus | - |
dc.subject | Vero Cells | - |
dc.title | A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, M.-S. | - |
dc.identifier.doi | 10.1038/s41467-020-20602-5 | - |
dc.identifier.scopusid | 2-s2.0-85099378040 | - |
dc.identifier.wosid | 000662809200015 | - |
dc.identifier.bibliographicCitation | Nature Communications, v.12, no.1 | - |
dc.relation.isPartOf | Nature Communications | - |
dc.citation.title | Nature Communications | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | human monoclonal antibody | - |
dc.subject.keywordPlus | immunoglobulin G | - |
dc.subject.keywordPlus | rbd protein | - |
dc.subject.keywordPlus | regdanvimab | - |
dc.subject.keywordPlus | remdesivir | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | virus RNA | - |
dc.subject.keywordPlus | virus spike protein | - |
dc.subject.keywordPlus | vitronectin | - |
dc.subject.keywordPlus | ACE2 protein, human | - |
dc.subject.keywordPlus | coronavirus spike glycoprotein | - |
dc.subject.keywordPlus | monoclonal antibody | - |
dc.subject.keywordPlus | neutralizing antibody | - |
dc.subject.keywordPlus | protein binding | - |
dc.subject.keywordPlus | spike protein, SARS-CoV-2 | - |
dc.subject.keywordPlus | virus antibody | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | animal tissue | - |
dc.subject.keywordPlus | antibody library | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | bacterium isolation | - |
dc.subject.keywordPlus | clinical assessment | - |
dc.subject.keywordPlus | clinical evaluation | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | convalescence | - |
dc.subject.keywordPlus | coronavirus disease 2019 | - |
dc.subject.keywordPlus | crystal structure | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | hamster | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human cell | - |
dc.subject.keywordPlus | in vitro study | - |
dc.subject.keywordPlus | in vivo study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | Mustela putorius furo | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | pandemic | - |
dc.subject.keywordPlus | peripheral blood mononuclear cell | - |
dc.subject.keywordPlus | protein domain | - |
dc.subject.keywordPlus | protein interaction | - |
dc.subject.keywordPlus | receptor binding | - |
dc.subject.keywordPlus | rhesus monkey | - |
dc.subject.keywordPlus | Severe acute respiratory syndrome coronavirus 2 | - |
dc.subject.keywordPlus | stereospecificity | - |
dc.subject.keywordPlus | symptom | - |
dc.subject.keywordPlus | therapy effect | - |
dc.subject.keywordPlus | virus load | - |
dc.subject.keywordPlus | virus replication | - |
dc.subject.keywordPlus | animal | - |
dc.subject.keywordPlus | chemistry | - |
dc.subject.keywordPlus | Chlorocebus aethiops | - |
dc.subject.keywordPlus | disease model | - |
dc.subject.keywordPlus | drug effect | - |
dc.subject.keywordPlus | drug therapy | - |
dc.subject.keywordPlus | immunology | - |
dc.subject.keywordPlus | Fc receptor | - |
dc.subject.keywordPlus | Mesocricetus | - |
dc.subject.keywordPlus | molecular model | - |
dc.subject.keywordPlus | mononuclear cell | - |
dc.subject.keywordPlus | protein conformation | - |
dc.subject.keywordPlus | Vero cell line | - |
dc.subject.keywordPlus | Cricetinae | - |
dc.subject.keywordPlus | Macaca mulatta | - |
dc.subject.keywordPlus | Mustela | - |
dc.subject.keywordPlus | SARS coronavirus | - |
dc.subject.keywordPlus | Angiotensin-Converting Enzyme 2 | - |
dc.subject.keywordPlus | Animals | - |
dc.subject.keywordPlus | Antibodies, Monoclonal | - |
dc.subject.keywordPlus | Antibodies, Neutralizing | - |
dc.subject.keywordPlus | Antibodies, Viral | - |
dc.subject.keywordPlus | Chlorocebus aethiops | - |
dc.subject.keywordPlus | COVID-19 | - |
dc.subject.keywordPlus | Disease Models, Animal | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Ferrets | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Leukocytes, Mononuclear | - |
dc.subject.keywordPlus | Macaca mulatta | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Mesocricetus | - |
dc.subject.keywordPlus | Models, Molecular | - |
dc.subject.keywordPlus | Protein Binding | - |
dc.subject.keywordPlus | Protein Conformation | - |
dc.subject.keywordPlus | SARS-CoV-2 | - |
dc.subject.keywordPlus | Spike Glycoprotein, Coronavirus | - |
dc.subject.keywordPlus | Vero Cells | - |
dc.subject.keywordPlus | angiotensin converting enzyme 2 | - |
dc.subject.keywordPlus | ct p 59 | - |
dc.subject.keywordPlus | d614g protein | - |
dc.subject.keywordPlus | fab protein | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.